TMCnet News
Nuvilex Technologies Recognized by the Singaporean Intellectual Property Intermediary, IPI SingaporeSILVER SPRING, Md., Jan 17, 2013 (GLOBE NEWSWIRE via COMTEX) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing natural products and cell and gene therapy solutions for the treatment of human diseases, announced today that its technologies, Cell-in-a-Box(R) and Bac-in-a-Box(R), developed by its subsidiary Austrianova Singapore (ASPL), have been recognized and profiled by the non-profit company, Intellectual Property Intermediary Singapore (IPI Singapore). The Cell-in-a-Box(R) and Bac-in-a-Box(R) products are proprietary living eukaryotic and bacterial cell encapsulation technological platforms developed by ASPL that can be used for a variety of living cell types. Both of them are unique platform technologies with the potential for such diverse uses as antibody production, treatment of diabetes, part of pancreatic cancer treatment regimen, treatments that employ stem cells, and for the improved use of probiotics, to name a few. The technologies have been shown to be robust for manipulations and injections and are non-immunogenic. They can be frozen with cells inside that can be recovered years later, and they allow cells to be expanded inside the capsules as mini bioreactors. Moreover, the technology has been shown to be safe and effective for multiple diseases in animal models as well as in human clinical trials for pancreatic cancer. IPI Singapore was launched in April 2011 as part of the Singapore Research, Innovation, and Enterprise 2015 Plan to contribute to the innovation and enterprise ecosystem in Singapore. IPI's overall aims include helping companies "identify, source, scan and assess technologies" as well as "facilitate technology transfer." The President and CEO of Nuvilex, Dr. Robert Ryan, stated, "We are pleased IPI Singapore has recognized our technology and will provide access to information about the technologies developed by our ASPL subsidiary. We believe our Company will receive increased exposure to the business and scientific communities due to the recognition by IPI Singapore. Through this recognition and our ongoing efforts, we hope to develop multiple unique products for commercialization from the Cell-in-a-Box(R) and Bac-in-a-Box(R) technology platforms." About Nuvilex Nuvilex, Inc. (OTCQB:NVLX) has been a provider of all-natural products for many years and has expanded its company to become an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for research and medicine. In the biotechnology area of Nuvilex, enhanced antibody production capabilities through encapsulation, our company's offerings will include cancer, diabetes, and other clinical treatments using the company's cell and gene therapy expertise and live-cell encapsulation technology. The Nuvilex, Inc. logo is available at //www.globenewswire.com/newsroom/prs/ pkgid=13494 Safe Harbor Statement This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws. CONTACT: Investor Relations Contact: Marlin Molinaro Marmel Communications, LLC Ph: (702) 434-8692 [email protected] http://media.globenewswire.com/cache/21252/small/14406.jpg <p>(Logo: http://media.primezone.com/cache/21252/int/14406.jpg) (Logo: http://media.primezone.com/cache/21252/int/14406.jpg) //www.globenewswire.com/newsroom/ti nf=MTMjMTAwMTY3NzMjMjEyNTI= |
